前列腺癌组织中miRNA-17-3p表达及其临床价值

doi:10.3969/j.issn.1671-7171.2023.09.005

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1244 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To analyze the expression and value of microRNA-17-3p (miRNA-17-3p) in prostate cancer (PCa) tissues.【Methods】A total of 92 PCa patients in urology were collected randomly in this study between December 2017 and July 2019 as the PCa group,meanwhile 92 patients with benign prostatic hyperplasia were selected as the control group. All of them were accepted surgery after admission and the tissues were preserved during operation,then the level of miRNA-17-3p were detected from tissues and compared with the two groups. The receiver operating characteristic (ROC) curve was used to evaluate the clinical value of miRNA-17-3p in diagnosing PCa; Pearson correlation was used to analyze the correlation between miRNA-17-3p,Gleason score and PSA.【Results】The level of miRNA-17-3p in the PCa group was significantly higher than that of the control group. ROC curve analysis results showed that the area under the curve (AUC,95%CI) of the value of miRNA-17-3p in diagnosis of PCa was 0.84 (0.77-0.90),diagnostic cut-off value was 23.19,and sensitivity and specificity were 58% and 77%,respectively. The ratios of TNM stage (stage Ⅲ+Ⅳ),PSA,Gleason score and low differentiation of PCa in high-expression of miRNA-17-3p group were higher than those in low miRNA-17-3p expression group. Pearson correlation analysis results showed that there was a significant positive correlation of miRNA-17-3p expression with PSA (r=0.659,P=0.036) and with Gleason score (r=0.332,P=0.004).【Conclusion】The miRNA-17-3p was up-regulation in PCa,and it can be severed as a potential indicator in diagnosis and evaluation of PCa.

Key words： Prostatic Neoplasms/PA MicroRNAs

Received: 23 November 2022

PACS:

R737.25

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DU Lingyun
	WANG Shanlong
	WANG Xiao

Cite this article:

DU Lingyun,WANG Shanlong,WANG Xiao. Expression and Value of miRNA-17-3p in Prostate Cancer Tissues[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(9): 1296-1298.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.09.005 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I9/1296

[1] 姚健翔,贾瑞鹏. PSMA PET显像在高危前列腺癌患者临床管理中应用的研究进展[J].东南大学学报(医学版),2019,38(6):1091-1095.
[2] SIEGEL R L,MILLER K D, JEMAL A. Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[3] PASHAEI E,AHMADY M,OZEN M,et al. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy[J].PLoS One,2017,12(6): e0179543.
[4] FENG S J,QIAN X S,LI H,et al. Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer[J].Oncol Lett,2017,14(6):6943-6949.
[5] 李鸣,孙光,贺大林,等. 中国前列腺癌诊断治疗指南[M]. 北京:人民卫生出版社,2011.
[6] EDGE S B,BYRD D R,COMPTON C C,et al.AJCC cancer staging manual[M].7th ed. New York:Springer-Verlag,2009:117-126.
[7] 杨欣,严彬,何佳.中国泌尿外科医师对前列腺癌放疗认知的3年变迁调查[J].中国现代手术学杂志,2020,24(5):359-364.
[8] 孙瑞芬,龚建瑜,邹海舰,等. miR-17-92基因簇在肿瘤发生发展中作用的研究进展[J].世界华人消化杂志,2017,25(20):1840-1853.
[9] ZHOU P,MA L,ZHOU J,et al. miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells[J].Int J Oncol,2016,48(4):1737-1748.
[10] 王勃霏,姜晓玲,卢斌,等. 骨肉瘤中miR-17-92基因簇作用的研究进展[J].肿瘤防治研究,2019,46(7):635-638.
[11] SMITH L,BAXTER E W,CHAMBERS P A,et al. Down-regulation of miR-92 in breast epithelial cells and in normal but not tumour fibroblasts contributes to breast carcinogenesis[J].PLoS One,2015,10(10):e0139698.
[12] KHAYAM N,NEJAD H R,ASHRAFI F,et al. Expression profile of miRNA-17-3p and miRNA-17-5p genes in gastric cancer patients with helicobacter pylori infection[J].J Gastrointest Cancer,2020,52(1):130-137.